Literature DB >> 1489578

Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1.

G Zwart1, T F Wolfs, M Valk, L Van der Hoek, C L Kuiken, J Goudsmit.   

Abstract

The major neutralization domain of HIV-1, contained in the third variable region (V3) of the external envelope, is highly variable at positions flanking a conserved glycine-proline-glycine sequence. We investigated the relation between V3 sequences of HIV-1 variants circulating in a host and that host's antibody specificity. Multiple V3 sequences were obtained directly, via PCR and subsequent cloning, from serum RNA or cellular DNA from 26 individuals (from 12 around seroconversion). Then, specificity of sera from these individuals to a panel of V3 peptides was determined. The specificity (best recognized peptide) of the early antibody response accurately reflected the virus population circulating around seroconversion in 12/12 individuals and 4/4 HIV-1-infected chimpanzees. A change in serum specificity at later stages of infection was rare: five years after seroconversion, only 3 of 46 individuals had a specificity that differed completely from that in the first year. However, the V3 domain of the virus does change over time, as evidenced by the poor correlation between V3 sequences obtained late in infection and V3 antibody reactivity at the same time point. Thus, in contrast to the accurate antibody response to HIV-1 variants early after infection, generally a specific response to variants emerging at later stages seemed to be absent or of low level. Instead, the early response appeared to be preserved. Finally, we made use of the observed accurate reflection to analyze the variation for the V3 domain of HIV-1 in the Netherlands by probing specificities of early sera from 129 Dutch seroconverting individuals. Specific reactivity to RKSIHIGPGRAFYTTG was found in 36%, to RKSINIGPGRAFYTTG in 12% and to RKSIPIGPGRAFYTTG in 18% of these Dutch sera.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489578     DOI: 10.1089/aid.1992.8.1897

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

2.  Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline.

Authors:  R B Markham; W C Wang; A E Weisstein; Z Wang; A Munoz; A Templeton; J Margolick; D Vlahov; T Quinn; H Farzadegan; X F Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

3.  Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period.

Authors:  V V Lukashov; C L Kuiken; J Goudsmit
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Authors:  N L Letvin; S Robinson; D Rohne; M K Axthelm; J W Fanton; M Bilska; T J Palker; H X Liao; B F Haynes; D C Montefiori
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.

Authors:  R Wyatt; N Sullivan; M Thali; H Repke; D Ho; J Robinson; M Posner; J Sodroski
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

6.  Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans.

Authors:  Thijs van Montfort; Adri A M Thomas; Georgios Pollakis; William A Paxton
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

7.  Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic.

Authors:  C L Kuiken; G Zwart; E Baan; R A Coutinho; J A van den Hoek; J Goudsmit
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

8.  Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.

Authors:  E Hogervorst; J de Jong; A van Wijk; M Bakker; M Valk; P Nara; J Goudsmit
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.

Authors:  L Buonaguro; E Del Guadio; M Monaco; D Greco; P Corti; E Beth-Giraldo; F M Buonaguro; G Giraldo
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.